This indeed makes it much more difficult to pin down and see which physicians are using which drugs, but from their own internal sales information each drug company will have sales from drug stores, so the overall business from a pre set territory can be derived, so perhaps a new curve in Pharma marketing...
The general public as a whole are lost when it comes to the complete understanding of how a clinical trial can benefit their potential treatment plans. There is enough information on the web by all means, but how do you get the information to an individual and explain both the potential benefits...
Posted to
The Medical Quack .... by Barbara Duck
on 11-07-2008
Filed under: Medically Related, Technology, drugs, healthcare, EHR, Pharma, PHR, clinical trials, Software integration, Point of Care, Personalized Clinical Trials
I will once more mention a potential change of paradigms here with educating the public. Each patient who took the drug is unique. Do we have any information on other drugs they were taking at the same time? Groups will continue to advise against the use until the full facts are known...
Posted to
The Medical Quack .... by Barbara Duck
on 10-31-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, healthcare, Pharma, PHR, FDA, Marketing, paradigms, personal heatlh records
The company has formed a “strategic partnership” with inVentiv Health , who does a lot of outsourcing for big Pharma, earlier this year, so perhaps some the sales and marketing slated for sales will be moving in this direction. Merck is not the only company investigating and pursuing this direction...
Reports of four experimental drugs held up at the FDA emerged in the first two days of this week. “ There’s almost certainly a bit of coincidence at work here, but it also seems to be one more sign of the tough safety climate at the agency these days .” Below are the 4 drugs. No doubt the...
I wonder if all the name brand companies will one day have nothing but generics? (grin). There’s always this interesting topic too, biosimilars. “Because biosimilars aren't exact duplicates of the original drugs, they don't violate the original drug's patent , enabling legal distribution...
Posted to
The Medical Quack .... by Barbara Duck
on 10-16-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, Pharma, Generic Drugs, Marketing, Pfizer, Biosimilars
The UK continues to say “no” to cancer drugs due to price. If you stop and look at the prices for cancer drugs, something along the line here is going to need to balance soon. It is great and wonderful to have the R and D and great breakthroughs that are occurring almost daily, but what good does...